home > ict > spring 2010 > mena machine
International Clinical Trials

MENA Machine

Maha Al-Farhan at ClinArt International examines legal and regulatory authorities and research ethics committees in the Middle East and North Africa (MENA)

Although clinical trials have been conducted in the MENA region since the 1990s, recently there has been rapid development in the infrastructure of clinical trials. New international players are establishing offices throughout the region, indicating its increasing international profile, and at the same time there are more enquires from physicians for training, or to be considered as investigators in ongoing clinical trials. There are also frequent questions about conducting clinical trials in the region from major pharmaceutical companies and global CROs.


We conducted a survey across the region to gain precise, accurate and up-to-date information about active clinical research ethics committees (REC), regional regulatory authorities (RA), the most sought after therapeutic area, and the recommended investigators. Two surveys were constructed, one aimed at RECs and the other at RAs. The RECs questionnaire was composed of 10 sections:

  • General information – this section was aimed at updating our REC contact list, as well as obtaining official information about the history of the REC, recently approved clinical research protocols, the composition of the committee, and hospitals covered by the REC.
  • Standard operating procedures – this examined which phases of clinical trials are accepted for review, published SOPs, regulations, guidelines and membership status, such as Office for Human research Protections (OHRP) registration.
  • Study protocol submission procedure – this considered the application form, documents to be submitted, any applicable fees, meeting frequencies, interim reporting, safety reporting and the final report.
  • Clinical trials agreements (CTAs) – this section investigated the role of RECs in reviewing CTAs, as well as any recommended fee structure and cost of tests and procedure that should be taken into consideration when reviewing a CTA.
  • Vulnerable subjects – here we asked who the REC considers to be vulnerable subjects, such as paediatrics, women, the handicapped and prisoners.
  • Patient recruitment policy – we asked the REC about their procedure with regards to different patient recruitment methodologies, such as mass media advertising, online advertisement, posters and so on.
  • Experienced investigators – we inquired about the most experienced investigators and most active applicants of research proposals. This section helped us differentiate between key opinion leaders who are usually recommended by the sponsor’s sales department and good investigators who are eager to contribute to science.
  • Electronic case report forms – although the internet is largely available throughout the region, in some hospitals there may be limits to internet access and use of the hospital’s IT infrastructure. This question provided a good starting point to recommend sites and to list potential limitations at the study site selection stage.
  • Storage of investigational products – this helped us decide the suitability of study sites for any given study protocol. We asked about dedicated clinical trials storage areas and available fridges and freezers. We also asked about access control and the name of the pharmacist responsible for clinical trials.
  • Research centres – this section examined which research centres are available in some hospitals, taking into account that more hospitals are seriously considering the establishment of suitably dedicated research centres. We wanted to find out the maximum amount of information regarding these research centres.

The RA questionnaire is very similar to the regulatory questionnaire, but there were additional sections examining:

  • Applicable laws
  • Networks of REC
  • Investigational products importation

Table 1: The acceptance of different phases of clinical trials
according to country
Country Phase I Phase II Phase III  Phase IV 
UAE     X
Qatar      X
Kuwait     X X
Saudi Arabia   X
Lebanon X X X
Morocco     X


Twelve RAs responded to our questionnaire: Jordan, Lebanon, Kuwait, Qatar, Bahrain, the UAE, Oman, Saudi Arabia, Egypt, Tunisia, Morocco and Algeria, as well as over 90 RECs. It is worth noting that, initially, few respondents answered all questions in our questionnaire; however, having presented this data at meetings and conferences, we started receiving more spontaneous information. We treat the database as a live document, whereby we apply ongoing updates as new information becomes available to us. We plan to conduct at least one major annual review of all data included in order to ensure its validity.

Ninety-three committees responded to the questionnaire; we checked their OHRP status and we were pleasantly surprised to learn that almost half are registered. We questioned some of those that were not registered with the OHRP for the reason why, and the most common answer was that it was not mandatory. We also asked about their written SOPs, regulations and guidelines: while almost all of the committees stated that they have their own guidelines, only 37 supplied us with their written documents. All except three confirmed that they follow GCP guidelines, with the number of members ranging from 5 to 24. The largest National Ethics Committee is the Jordan Ministry of Health.

As for the submission procedure, all RAs and RECs accept submissions made by principal investigators, 23 would also accept submissions made by study sponsors and CROs, and two RAs and 14 RECs confirmed that they charge a fee that ranges from $500 to $3,000. It is a general requirement that clinical trial agreements and financial compensation are presented in the submission dossier of clinical trials. Often the REC questions the cost implication to the hospital overheads, 13 committees had actually decided a fee structure that includes the institute as well as the investigator. Fee per patients is also scrutinised in order to ensure that the clinical trial in consideration will not abuse hospital resources or implicate additional costs to the patient.

As for accepted practices of advertising for study subjects’ recruitment, nine committees have some sort of policy with regard to patient advertisement. The remaining committees do not have such a policy, but they generally agreed that it should be reviewed in order to avoid coercion.

We identified over 520 experienced clinical research investigators working in over 100 hospitals, with the most common approved clinical trials being in the areas of oncology, neurology, endocrinology, haematology, cardiovascular, respiratory, infectious diseases, gastrointestinal, and orthopaedic/rheumatology. We analysed about 100 hospitals that had participated in the survey to identify the most suitable clinical research sites. Our rating procedure was based on:

  • Research infrastructure
  • Number of experienced investigators
  • History of clinical trials
  • Size of the hospital

Table 2 summarises our findings, which are far from exhaustive. Some good sites were excluded from this list due to a lack of response from the hospital research offices.

Table 2: Highly rated clinical research centres in the MENA region    
Country Clinical Research Centre 1  Clinical Research Centre 2  Clinical Research Centre 3 
Jordan  King Hussein Cancer Centre  Jordan Hospital  Jordan Unviversity Hospital 
Lebanon  AUB Medical Centre Foundation  Hotel Deiu  Saint George Hospital 
Kuwait  Mubarak AlKabeer Hospital  AlAmiri Hospital  Dasman Center 
Qatar  Hamad Medical Hospital  AlAmal Hospital  Weill Cornell Medical College - and SIDRA 
Bahrain  Salmaniya Complex  Bahrain Defense Force Hospital   
UAE  Sheikh Khalifa Medical City  Tawam Hospital  Rashid Hospital 
Oman  Sultan Qaboos University Hospital  Royal Hospital  Nizwa Hospital 
Saudi Arabia  King Faisal Specialist Hospital  National Guard Hospital  King Saud/King Abdul Aziz University Hospital 
Egypt  Kiser El-Aini  AinShams University  Alexandria University 
Tunisia  Farahat Hatched University  Pasteur Institute  Institute of Salah Azaiez 
Morocco  Faculty of Medicine and Pharma at the University of Casablanca  Institute Pasteur du Maroc  Centre d'Oncologie Clinique le Littoral 
Algeria  Marie Curie Cancer Centre  MOH Hospitals   

Eleven committees stated that they routinely accept applications involving eCRFs, with appropriate restrictedaccess computer areas available. This is not to assume that the remaining hospitals do not accept eCRFs, rather it is an indication for further attention to be given to IT infrastructure when validating sites selected for eCRFs studies – for example, the provision of mobile internet connections and computers. Twenty-four committees stated that they were aware of a dedicated research department in their institute, and a similar number stated that all study medication was stored in specialised compartments in the main hospital pharmacy department under the supervision of a dedicated pharmacist.

Questions directed at RAs were similar to those asked of committees with the addition of a further section related to the importation of investigational product. In order to import study medication/investigational product, regional RAs were in unison in their requirements, stating that they need clinical trial approval and product details, such as name, LOT and batch number, expiry data, certificate of analysis, GMP certificate, certificate of origin, and a copy of the IP label in English and in Arabic. Since most countries in the MENA region do not accept applications for early-phase clinical trials (see Table 1); these regulatory authorities also requested marketing authorisation documents in the country of origin.


Our survey has established a road map for conducting clinical trials in the MENA region. We do recommend updating this information twice yearly as laws and regulations are being clarified continuously. It is very important for those planning their studies to have a full understanding of specific capabilities and challenges before considering the region.

The author would like to thank the ClinArt team for their contributions and suggestions, and Dr Antoinne Estephan, who inspired the idea of building a database of centres of clinical research excellence.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Maha Al-Farhan is the chair of the Gulf Countries Chapter of the Association of Clinical Research Professionals (ACRP) – a US-based Association that aims to provide global leadership to promote integrity and excellence for the clinical research profession. Through the ACRP, Maha has coordinated and conducted numerous ACRP-certified training courses in the Gulf and Saudi Arabia, and is actively coordinating networking meetings and conferences. Maha is also a founding member of the first regional clinical research organisation in the MENA region, ClinArt International, where she works as the CEO.
Maha Al-Farhan
Print this page
Send to a friend
Privacy statement
News and Press Releases

Huge boom in Korean Pharma reported at CPhI Korea

Amsterdam, 19th September 2019: The recently-closed CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – has seen a surge in growth across domestic and international pharma companies, as well as a sizable rise in overall attendees. As reported earlier this year in the provisional findings of the CPhI Pharma Index[1], Korea has seen a rapid growth in its international reputation (seeing its ‘overall competitiveness’ rise 14% in the last two years), which is now translating into a sizable growth in the market and at the event.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services


With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement